Compare Ishares Msci Italy ETF (EWI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Organon & Co. Common Stock — how do they compare? Ishares Msci Italy ETF trades at $56.06 (market cap $1.20B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 3× Ishares Msci Italy ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 55 Days and Organon & Co. Common Stock for 0 Days on average.
| EWI | OGN | |
|---|---|---|
Market Cap | $1.20B | $3.62B |
Volume | 332,777 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $13.81 |
52-Week Low | $50.47 | $5.70 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.66 with a 0.87% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral with RSI levels suggesting potential oversold conditions. The ETF offers concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU-supported infrastructure investments.
The outlook remains cautious due to eurozone economic pressures and ECB tightening, but EWI provides strategic access to Italy's banking and infrastructure investment cycle. Key risks include eurozone business confidence declines and energy price volatility. Analyst sentiment is mixed with technical weakness offset by long-term structural opportunities in Italian markets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
